Malignant tumors of the skeleton
- by age: Ewing's sarcoma (10-20 years), osteosarcoma (15-25 years), malignant fibrous histiocytoma (20-30 years), chondrosarcoma (over 50 years), bone metastases (over 40 years)
- treatment in general: biopsy → CHT (Ewing + RT) → wide resection/amputation → adjuvant CHT
Osteosarcoma is a malignant primary bone tumor (the 2nd most common primary malignant bone tumor after the exclusion of multiple myeloma). It most often affects the long bones of the lower limb near the knee joint. Osteosarcoma grows in the bone, which it destroys, and invades the soft tissues around the bone. It soon metastasizes, especially via the hematogenous route to the lungs, other bones, and the brain. It is one of the most common malignant bone tumors, along with chondrosarcoma. The age group most at risk is the 10 - 20 years age group. Every year, 4 out of one million children are diagnosed with osteosarcoma.
Classification[edit | edit source]
- Central (medullary, conventional) osteosarcoma is a highly malignant tumor (the most common malignant bone tumor) that occurs in individuals under 20 years of age (one of the most common tumors in this age group) or in older individuals due to Paget's disease, fibrosis dysplasia, and similar pathological bone processes. It can affect any bone (more often the femur, tibia, humerus, at the transition from the diaphysis to the metaphysis). It soon metastasizes (mainly to the lungs, brain, other bones). It is clinically manifested by persistent dull pain, mild swelling of the bone and mild fever. The tumor begins to grow in the metaphyseal marrow, infiltrates the cortex below the periosteum, and then can grow into the adjacent soft tissues. Osteoid formation is evident microscopically (non-mineralized bases) by tumor cells (the tumor consists of osteoblasts). In different proportions, bone, and cartilaginous and fibrous tissue are represented (or with wide vascular spaces - telangiectatic osteosarcoma - the most malignant form of osteosarcoma). Depending on which type of tissue predominates, osteosarcoma can be:
- Fibroplastic - spindle cell ligament;
- Chondroplastic - tumor of cartilaginous tissue with atypical spindle cell elements;
- Osteoplastic - islets or beams of osteoid (can be mineralized), tumor osteoblasts have atypical or polymorphic nuclei (the only sign that it is a tumor process).
- Peripheral (superficial) osteosarcoma: creates a painful protuberance on the bone surface. X-ray shows secondary periosteal ossification. It includes, for example, parosteal (juxtacortical) osteosarcoma with a very good prognosis, osteosarcoma with a high degree of malignancy, and periosteal osteosarcoma.
Clinical picture[edit | edit source]
- Pain in the affected bone, typically resting and nocturnal (i.e., without physical exertion)
- With tumor growth, solid swelling occurs, which may not be painful to the touch (typically around the knee joint).
- At an advanced stage, a pathological fracture of the relevant bone might occur.
- Non-specific general symptoms - night sweating, fever, weight loss
- Cough and difficulty breathing - lung metastases. 
Diagnosis[edit | edit source]
- Elevated phosphatase levels are a biochemical marker of bone tumors
- Simple X-ray (typically areas of osteolysis and newly formed bone, unbounded, exhibits periosteal reaction, Codman's triangle = space bounded by elevated periosteum, bone surface and tumor), NMR
- Definitive diagnosis histologically (sarcoma stroma, osteoid formation by tumor osteoblasts)
- CT of the lungs and scintigraphic examination of the skeleton– metastases.
Treatment[edit | edit source]
- Chemotherapy (adriamycin, high-dose MTX, leucovorin, cisPt, BCD, ifosfamide)
- Radical surgical removal of the tumor (amputation or limb saving surgery)
- Osteosarcoma generally has a low sensitivity to radiotherapy.
Prognosis[edit | edit source]
Patients with a radically operated tumor and a good response to chemotherapy have up to an 80% chance of recovering.
Ewing's sarcoma (EWS) belongs to the sarcomas of the Ewing group: EWS, PNET (primitive neuroectodermal tumor), Askin's tumor (Ewing on the chest wall).
It is the 2nd most common malignant bone tumor in children and adolescents, the highest incidence between 5–30 years of age. Early metastasis to the lungs is typical.
It most often develops in the bone marrow of the diaphysis of long bones (mainly femur, tibia). It often mimics acute osteomyelitis: subfebrile, leukocytosis, increased sedimentation, pain, including positive scintigraphy.
RTG: osteolytic changes with permeative bone destruction + periosteal reaction.
Therapy: 1. neoadjuvant CHT , 2. radical surgical resection, 3. intraoperative / subsequent RT , 4. adjuvant CHT.
Prognosis: 5-year survival 60-76% (in case of no metastases).
Chondrosarcoma is one of the most common malignant bone tumors, it is an adult tumor.
- In the metaphysis of the proximal part of the humerus, femur, tibia, , and elsewhere.
- Typically: a man aged 40-70 years, complains of pain in the gluteal region, the area of the hip joint or pain in the equilateral thigh / knee, attacks the affected limb, the pain gradually worsens and does not subside at rest.
- X-ray: intraosseous osteolytic lesion with islets calcification.
- Histological picture: lobularly arranged masses of cartilaginous tissue with cellular atypia.
- Therapy:: single treatment surgical removal of the tumor: broad / radical resection of the tumor, ev. metastasectomy in solitary lung disease.
Links[edit | edit source]
Related articles[edit | edit source]
References[edit | edit source]
- SOSNA, A. – VAVŘÍK, P. – KRBEC, M., et al. Základy ortopedie. 1. edition. Praha : Triton, 2001. ISBN 80-7254-202-8.
- GALLO, Jiří, et al. Ortopedie pro studenty lékařských a zdravotnických fakult. 1. edition. Olomouc : Univerzita Palackého v Olomouci, 2011. ISBN 978-80-244-2486-6.
Plasmocellular myeloma, or plasmacytoma, is a malignant tumor of the plasma cells. It is usually found in the bone marrow, where it destroys bone and can cause pathological fractures. If there are more deposits, we call it multiple myeloma (Kahler's disease). Tumor cells produce protein chains - paraprotein. However, there are rarely non-secretory myelomas in which no paraprotein can be detected in serum.
Pathology[edit | edit source]
Macroscopy[edit | edit source]
Myeloma takes the form of dark red osteolytic deposits in the bone marrow (calva, vertebrae, pelvis, humeral shaft, femur).
Complications[edit | edit source]
- Pathological fractures (there is a risk of spinal cord lesions in the case of vertebrae).
- AL amyloidosis.
- Myeloma kidney - clogging of tubules by protein chains - ' Bence Jones protein' .
Life threatening conditions[edit | edit source]
- Failure of an organ affected by amyloidosis,
- bronchopneumonia - develops after vertebral fracture and spinal cord injury,
- bone marrow tumor generalization infection (same as leukemia).
Clinical part[edit | edit source]
Epidemiology[edit | edit source]
The disease affects men more often than women (1.5: 1). The incidence is rising from the age of 50, the median age is 70 years. The incidence in the Czech Republic is 3-4: 100,000 inhabitants / year. The etiology of the disease is unknown. It is almost non-existent in childhood and very rare in young people.
Clinical symptoms[edit | edit source]
The initial period may be completely asymptomatic (in indolent lymphomas), but> 70% of patients are dominated by pain in the back and ribs. Pain is tied to physical activity.
The clinical picture is formed by a set of symptoms hidden under the acronym CRAB:
- Calcium – hypercalcemia, which is associated with bone loss. Hypercalcemia also causes depression, lethargy and weakness.
- Renal failure – renal failure due to tubulopathy, uncommon myeloma,
- Anemia – normocytic normochromic anemia is the most common symptom, it is associated with weight loss, fatigue, shortness of breath and paleness
- Bone – Bone involvement - very common, tumor cells in the bone marrow produce osteoclasts activating factors, leading to bone osteolysis and pathological fractures that occur in up to 70% of patients.
Susceptibility to infections, manifestations of hyperviscous syndrome (headache, vision disorders) and palpable infiltrates over osteolytic deposits (especially on the skull) also contribute to the clinical picture.
Examination methods[edit | edit source]
- X-ray - reveals pathological deposits (often the skull and spine are affected, but myeloma may be in any bone), as well as CT, MRI, PET,
- detection of paraprotein in blood – Plasma protein electrophoresis (see picture), serum paraprotein concentration is usually> 30 g/l,
- detertion of free chain (FLC) – the most sensitive method, it also detects non-secretory myeloma, when the determination of the paraprotein would be negative, the normal ratio of kappa: lambda light chains is 2: 1, in the case of myeloma it is, for example, 350: 1,
- detection of Bence Jones protein in the urine,
- bone marrow examination - the number of plasma cells usually exceeds 10% of all nuclear cells in the marrow, as well as immunohistochemical and cytogenetic examination (occurrence of deletions, trisomies that are of prognostic significance),
- cytogenetic examination - numerical and structural changes of chromosomes, important for prognosis
- laboratory examination,
- normocytic normochromic anemia, mild leukopenia and thrombocytopenia
- often increased sedimentation,
- renal function - increased urea and creatinine,
- examination of LD, thymidine kinase and beta 2 -microglobulin, hyperuricemia - their increased values have a negative prognostic significance.
Clinical stages and variants[edit | edit source]
Clinical stages[edit | edit source]
Classification according to Durie and Salmon:
- clinical stage I – paraprotein concentration IgG <50 g / l, or IgA <30 g / l, proteinuria <4 g / 24 hours, no osteolytic changes without hypercalcemia,
- clinical stage II – values are between stages I and III,
- clinical stage III – araprotein IgG> 70 g / l, or IgA> 50 g / l, proteinuria> 12 g / 24 hours, multiple bone deposits, hypercalcemia> 2.75 mmol / l, hemoglobin concentration <85 g / l,
- subclassification A, B according to the value of serum creatinine (renal impairment),
- subclassification A – serum creatinine ≤ 177 μmol/l,
- subclassification B – serum creatinine > 177 μmol/l.
Clinical variants[edit | edit source]
- smoldering myeloma,
- indolent myeloma,
- stage I multiple myeloma,
- stage II and III multiple myeloma,
- solitary plasmacytoma.
Therapy[edit | edit source]
- If myeloma is asymptomatic, it is not treated, it is only monitored,
- if symptomatic, it is treated:
- younger patients are indicated for autologous hematopoietic stem cell transplantation,
- elderly patients are indicated for chemotherapy,
- chemotherapy - cyclophosphamide and dexamethasone (or thalidomide) are used as standard, since 2009 registered in the Czech Republic for primary therapy bortezomib 
- radiotherapy - for painful bone deposits,
- palliative treatment - in patients with severe comorbidities, melphalan and prednisone, or radiotherapy.
Other rarer skeletal malignancies[edit | edit source]
Links[edit | edit source]
[edit | edit source]
Reference[edit | edit source]
- FN Brno. Osteosarkom [online]. Klinika dětské onkologie FN Brno, [cit. 2011-01-02]. <https://www.fnbrno.cz/detska-nemocnice/klinika-detske-onkologie/informace-pro-pacienty/t2698>.
- PASTOR, Jan. Langenbeck's medical web page [online]. [cit. 18.04.2010]. <https://langenbeck.webs.com/>.
- ČEŠKA, Richard – ŠTULC, Tomáš. Interna. 2. edition. 2015. 909 pp. ISBN 978-80-7387-895-5.
- ČEŠKA, Richard. Interna. 1. edition. Triton, 2010. 855 pp. pp. 710. ISBN 978-80-7387-423-0.
- https://www.myeloma.cz/index.php?pg = multiple-myeloma-treatment-bortezomib-velcade
References[edit | edit source]
- DUNGL, P.. Ortopedie. 1. edition. Grada Publishing, 2005. ISBN 80-247-0550-8.
- SOSNA, A. – VAVŘÍK, P. – KRBEC, M.. Základy ortopedie. 1. edition. Triton, 2001. ISBN 80-7254-202-8.
- GALLO, Jiří. Ortopedie pro studenty lékařských a zdravotnických fakult. 1. edition. Univerzita Palackého v Olomouci, 2011. ISBN 978-80-244-2486-6.